Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics.
Interleukin-17 receptor
Loss of response
Psoriasis area and severity index
Static physician’s global assessment
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
26
02
2020
pubmed:
14
6
2020
medline:
14
6
2020
entrez:
14
6
2020
Statut:
ppublish
Résumé
While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents. It may therefore be beneficial for patients whose psoriasis fails to respond to one biologic to switch to a different biologic therapy, in particular one with a different mechanism of action. However, it remains unclear how prior biologic exposure or lack of response affects the efficacy and safety of subsequent biologics in patients with moderate-to-severe psoriasis. Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has previously been shown to be efficacious in treating moderate-to-severe psoriasis in three large phase 3 trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3). In this review, we summarize the efficacy and safety of brodalumab in patients with moderate-to-severe psoriasis and a history of biologic exposure. Further, we describe improvements in skin clearance and quality of life measures as well as safety in patients who had inadequate response to ustekinumab and who were rescued with brodalumab therapy. Lastly, we discuss improvements in skin clearance following rescue with brodalumab in patients whose disease failed to respond to secukinumab and ixekizumab. The findings of our review suggest that brodalumab is a safe and efficacious treatment regardless of past biologic use or lack of response to prior biologic therapy.
Identifiants
pubmed: 32533554
doi: 10.1007/s13555-020-00411-w
pii: 10.1007/s13555-020-00411-w
pmc: PMC7367951
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
615-621Références
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–72.
doi: 10.1016/j.jaad.2018.11.057
Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13:848–53.
pubmed: 25007369
Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44:1015–9.
doi: 10.1111/1346-8138.13860
Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Investig Dermatol. 2015;135:2632–40.
doi: 10.1038/jid.2015.208
Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178:114–23.
doi: 10.1111/bjd.15750
Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019;180:306–14.
doi: 10.1111/bjd.17318
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418–31.
doi: 10.1016/j.jaad.2016.11.042
Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77:855–62.
doi: 10.1016/j.jaad.2017.06.153
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–28.
doi: 10.1056/NEJMoa1503824
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273–86.
doi: 10.1111/bjd.14493
Union Register of medicinal products for human use. European Commission. https://ec.europa.eu/health/documents/community-register/html/h1155.htm . Accessed 20 Mar 2020.
Siliq [package insert]. Bridgewater: Valeant Pharmaceuticals North America, LLC; 2017.
Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9.
doi: 10.1056/NEJMoa1109017
Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192:3828–36.
doi: 10.4049/jimmunol.1301737
Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179:320–8.
pubmed: 29488226
Green L, Menter A, Boh E, Israel R, Jacobson A. Brodalumab in patients with or without previous use of biologic agents: long-term findings from two phase 3 psoriasis studies. In: Poster presented at: 77th Annual Meeting of the American Academy of Dermatology; March 1–5, 2019; Washington, DC.
Strober B, Bhatia N, Keegan B, Armstrong A, Israel RJ, Jacobson A. Post hoc analysis of long-term efficacy and safety of brodalumab by prior anti-TNF biologic status. In: Poster presented at: Maui Derm for Dermatologists; January 26–30, 2019; Maui, HI.
Kerdel F, Lewitt GM, Drew S, Jacobson A. Long-term efficacy and safety in clinical trials of brodalumab by prior response to adalimumab. In: Poster presented at: 78th Annual Meeting of the American Academy of Dermatology; March 20–24, 2020; Denver, CO.
Lebwohl M, Green L, Bettencourt M, Fretzin S, Jacobson A. Long-term efficacy and safety of brodalumab in patients with psoriasis whose disease did not respond to prior biologics. In: Poster presented at: 39th Annual Fall Clinical Dermatology Conference
Blauvelt A, Tyring S, Langley R, Rastogi S, Pillai R, Israel RJ. Efficacy and safety of brodalumab in patients with inadequate response to ustekinumab: analysis of two phase 3 psoriasis studies. In: Poster presented at: 76th Annual Meeting of the American Academy of Dermatology; February 16–20, 2018; San Diego, CA.
Kimmel G, Chima M, Kim H-J, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81:857–9.
doi: 10.1016/j.jaad.2019.05.007